Navigation Links
New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohn's Patients
Date:10/26/2009

s adverse events (SAEs) was 5.6 percent, including one case each of tuberculosis, pyelonephritis, and pneumonia.

About Crohn's Disease

Crohn's disease is a chronic, progressive, destructive disorder that causes inflammation of the gastrointestinal (GI) tract, most commonly at the end of the small intestine (the ileum) and beginning of the large intestine (the colon). The inflammation may be caused by the presence of high levels of Tumor Necrosis Factor (TNF) found in people with Crohn's disease. If not effectively treated, it may result in the need for surgery and hospitalization. Crohn's disease has been estimated to affect as many as half a million Americans. People with Crohn's can experience an ongoing cycle of flare-up and remission throughout their lives. Together with ulcerative colitis, Crohn's disease is an inflammatory bowel disease (IBD).

About CIMZIA® (certolizumab pegol)

CIMZIA is the only PEGylated anti-TNF (Tumor Necrosis Factor). CIMZIA( )has a high affinity for human TNF-alpha, selectively neutralising the pathophysiological effects of TNF-alpha. Over the past decade, TNF-alpha has emerged as a major target of basic research and clinical investigation. This cytokine plays a key role in mediating pathological inflammation, and excess TNF-alpha production has been directly implicated in a wide variety of immunological diseases. The U.S. Food and Drug Administration (FDA) has approved CIMZIA for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderate to severe active disease who have had an inadequate response to conventional therapy and for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). CIMZIA was approved in Switzerland for induction of a clinical response and for the maintenance of a clinical response and remission in patients with active Crohn's disease who have not responded adequately to co
'/>"/>

SOURCE UCB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
2. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
3. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
4. Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohns Disease
5. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
6. e-Zassi.com Provides Industry With Online U.S. FDA Regulatory Calculator for Rapid Medical Device Technology Assessment
7. Access Pharmaceuticals Provides Update on MuGard Commercial Launch and First European Clinicians Feedback
8. New ALS Patient Simulator Advanced Provides Valuable Training for EMS Teams and In-Hospital Emergency Personnel
9. CardioGenics Holdings Inc. Provides Update on FINRA Submission Regarding Name Change
10. Young Innovations, Inc. Provides Third Quarter Conference Call Details
11. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... FRANCISCO, Calif. , July 29, 2015 ... antibody company focused on developing innovative therapies to benefit ... focus on oncology, announced today that it received a ... ("NASDAQ") notifying the company that it is now compliant ... on the NASDAQ Global Market and is no longer ...
(Date:7/29/2015)... DUBLIN , July 24, 2015 ... the addition of the "Global Wound Care ... Kingdom, United States, Japan, Canada, China, India, Brazil, ... The report provides a competitive ... in terms of both product offerings and product ...
(Date:7/29/2015)...   Decision Resources Group finds that the ... will continue to be hindered in the near ... a longer timeline, however, the outlook is improved. Expanding ... increase the prevalence of osteoarthritic damage and sports-related injuries ... tissue solutions. Coupled with continuing economic recovery across ...
Breaking Medicine Technology:KaloBios Regains Compliance with NASDAQ Minimum Bid Price Requirement 2KaloBios Regains Compliance with NASDAQ Minimum Bid Price Requirement 3KaloBios Regains Compliance with NASDAQ Minimum Bid Price Requirement 4Global Wound Care Markets 2015 2The Long-Term Outlook for European Sports Medicine Device Markets Remains Positive, with Economic Recovery and Expanding Patient Populations Supporting Growth Through 2023 2The Long-Term Outlook for European Sports Medicine Device Markets Remains Positive, with Economic Recovery and Expanding Patient Populations Supporting Growth Through 2023 3
... , May 7 Young Innovations, Inc. (Nasdaq: YDNT ) today ... per share, payable June 15, 2010 to all shareholders of record on ... , The Company also ... Mr. McKey joined the Company in November 2003 . He has assumed positions ...
... 7 Patients treated with the Zilver® ... two years, according to interim results from the ... late-breaking clinical trial at the Society for Cardiovascular ... The prospective, single-arm study is ongoing to evaluate ...
Cached Medicine Technology:Young Innovations, Inc. Board of Directors Declares Quarterly Dividend and Announces Election of New Officer 2Drug-Eluting Peripheral Stent Continues to Show Positive Data at Two Years 2Drug-Eluting Peripheral Stent Continues to Show Positive Data at Two Years 3
(Date:7/29/2015)... Washington, D.C. (PRWEB) , ... July 29, 2015 ... ... released a white paper, Our Best Shot: Expanding Prevention through Vaccination in ... underutilization in seniors and offers recommendations on how industry, government, and health care ...
(Date:7/29/2015)... ... July 29, 2015 , ... Join Luz Delia Gerber and Abbi ... that Well-Being begins with understanding how the body actually works. A state of mindfulness ... Guests will receive tips on how to forge this new relationship with their bodies. ...
(Date:7/29/2015)... ... July 29, 2015 , ... Topical BioMedics, ... Topricin® Pain Relief and Healing Cream designated as the nonprofit’s natural pain reliever ... actively addressing Line of Duty Deaths (LODD) and the high rate of pain ...
(Date:7/29/2015)... ... , ... According to the Miami Herald on July 18th acupuncture ... disorders. Acu-detox may begin taking off in the South Florida community as more detox ... acupuncture is not a new practice, it is not widely used, but has yielded ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... For the ... to be featured in the list of the 50 fastest growing companies in Jacksonville. ... around the business community. On July 16th, a team of Vast Bridges staffers were ...
Breaking Medicine News(10 mins):Health News:Vaccination Rates in Older Adults Fall Short of Targets 2Health News:Vaccination Rates in Older Adults Fall Short of Targets 3Health News:Pampering and Empowerment Abound at Final Event in Luz Delia Gerber’s Book Unveiling 2Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 2Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 3Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 4Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 5Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 6Health News:Miami Drug Rehab Introduces Acupuncture to Line of Holistic Healing for Addiction 2Health News:Miami Drug Rehab Introduces Acupuncture to Line of Holistic Healing for Addiction 3Health News:Vast Bridges Continues Its Swift Growth 2
... THURSDAY, April 28 (HealthDay News) -- Women in powerful positions are ... to new research. It,s widely believed that men are more ... to be a more important factor than gender, according to the ... "There has been a lot of research in the past ...
... a tissue spacer in the prostate-rectal inter-space is an ... cancer patients receiving radiation therapy, according to research presented ... Therapy Symposium in Atlanta. This symposium is sponsored by ... Society of North America (RSNA)., Even though prostate cancer ...
... sufficient follow-up after breast conserving therapy (BCT) for breast ... the Cancer Imaging and Radiation Therapy Symposium in Atlanta. ... Radiation Oncology (ASTRO) and Radiological Society of North America ... clinical relevance and utility of an interval mammogram (IM) ...
... scans and 3D printing technology are proving useful in ... fast and affordable way to build 3D models for ... CT patient images into 3D solid models using a ... construction. An advantage of 3-D models is that they ...
... of hospitalization have discouraged primary care doctors from seeing ... use of "hospitalists," a new physician specialty focused on ... field mean that frequently hospitalized patients also may need ... expert on hospital care at the University of Chicago. ...
... Dotinga HealthDay Reporter , THURSDAY, April 28 (HealthDay ... a much higher risk for developing potentially fatal blood clots, ... new study. The researchers report that extra weight and ... either alone. "Tall and obese men had more than ...
Cached Medicine News:Health News:Powerful Women as Likely to Cheat as Men, Study Finds 2Health News:Tissue spacers reduce risk of rectal injury for prostate cancer patients 2Health News:Frequently hospitalized patients may benefit from new medical specialty focused on their needs 2Health News:Tall, Obese Men More Prone to Leg Clots: Study 2
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Glucose tubes contain an anti-coagulant and a stabiliser. The tubes are ideal for glucose and lactate determinations....
Inquire...
BD Vacutainer® Fluoride Tubes - Glass...
Medicine Products: